O013 Preliminary Results from a Phase 1 Study of ALKS 2680, an Orexin-2 receptor Agonist, in Healthy Participants and Patients with Narcolepsy or Idiopathic Hypersomnia

Abstract Introduction ALKS 2680, a potent, brain-penetrant, highly selective orexin-2 receptor (OX2R) agonist, is being developed for treatment of narcolepsy and other hypersomnias. We report preliminary results from the ALKS 2680 first-in-human study. Methods This randomized, double-blind, phase 1...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Sleep advances. 2023-10, Vol.4 (Supplement_1), p.A5-A6
Hauptverfasser:	Yee, B, Chapman, J, Grunstein, R, Argent, C, D’Rozario, A, Hopkinson, C, Ramos, J, Landry, I, Yagoda, S, Rege, B
Format:	Artikel
Sprache:	eng
Schlagworte:	Oral Presentations
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!